Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 44-49

  Chiu, Mona L S ^a   Hu, M ^a   Ng, M H L ^a   Yeung, C K ^b   Chan, J C Y ^b   Chang, M M ^a   Cheng, S H ^a   Li, L ^a   Tomlinson, B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; HLA B ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG TOLERANCE; FEMALE; GENOTYPE; HONG KONG; HUMAN; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEVERE CUTANEOUS ADVERSE REACTION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DRUG ERUPTIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-B ANTIGENS; HONG KONG; HUMANS; MALE; MIDDLE AGED; URICOSURIC AGENTS;

EID: 84863335462     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10894.x     Document Type: Article

References (32)

1. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14:281-6. (Pubitemid 34439094)
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272-85. (Pubitemid 24333193)
3. Atzori L, Pinna AL, Mantovani L et al. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department - Cagliari University (Italy). J Eur Acad Dermatol Venereol 2011; [Epub ahead of print] DOI: 10.1111/j.1468-3083.2011.04313.x.
4. Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58:25-32. (Pubitemid 350298142)
5. Lin MS, Dai YS, Pwu RF et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 2005; 35:188-90.
6. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32. (Pubitemid 34215071)
7. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297-306.
8. Man CB, Kwan P, Baum L et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015-18. (Pubitemid 46763406)
9. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4134-9.
10. Jung JW, Song WJ, Kim YS et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26:3567-72.
11. Kang HR, Jee YK, Kim YS et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011; 21:303-7.
12. Kaniwa N, Saito Y, Aihara M et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-22.
13. Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19:704-9.
14. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99-107.
15. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010; 11:973-87.
16. Middleton D, Hawkins BR, Williams F et al. HLA class I allele distribution of a Hong Kong Chinese population based on high-resolution PCR-SSOP typing. Tissue Antigens 2004; 63:555-61. (Pubitemid 38748005)
17. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-7.
18. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27:337-43. (Pubitemid 23086961)
19. Peyriere H, Dereure O, Breton H et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155:422-8. (Pubitemid 44050579)
20. Sassolas B, Haddad C, Mockenhaupt M et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88:60-8.
21. Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 1956; 20:309-11.
22. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92-6. (Pubitemid 23029676)
23. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003; 4:561-72. (Pubitemid 36995078)
24. Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138:1019-24. (Pubitemid 34875605)
25. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47-56. (Pubitemid 14216359)
26. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009; 11:135-40.
27. Dalbeth N, Kumar S, Stamp L et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33:1646-50. (Pubitemid 44168841)
28. Emmerson BT. The management of gout. N Engl J Med 1996; 334:445-51. (Pubitemid 126528536)
29. Day RO, Graham GG, Hicks M et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46:623-44. (Pubitemid 47204850)
30. Hamanaka H, Mizutani H, Nouchi N et al. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol 1998; 23:32-4. (Pubitemid 28218196)
31. de Vries JX, Voss A, Ittensohn A et al. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. Clin Investig 1994; 72:1076-81.
32. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-79. (Pubitemid 351214284)